Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28604834 | 0.98 | RECQL (0.31) | RECQLCA1CA2CA12CA7 | |
| SCHEMBL19154262 | 0.91 | CA1 (0.32) | RECQLCA1CA2 | |
| SCHEMBL15868130 | 0.81 | CA1 (0.33) | RECQLCA1CA2CA12CA7 | |
| SCHEMBL329520 | 0.81 | — | — | |
| SCHEMBL128775 | 0.78 | TP53 (0.31) | — | |
| Hydrochloric Acid SCHEMBL28792672 | 0.78 | TP53 (0.31) | — | |
| SCHEMBL15223842 | 0.78 | ALDH1A1 (0.41) | RECQL | |
| SCHEMBL16265089 | 0.76 | KDM4E (0.33) | — | |
| SCHEMBL59397 | 0.76 | — | — | |
| SCHEMBL14955502 | 0.76 | TP53 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024097327-A1 | CANNABINOID FORMULATIONS AND USE FOR TREATMENT OF EMOTIONAL DISORDERS AND SEXUAL DYSFUNCTION | PROGRESSIVE THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | claimed |
| WO-2019008472-A1 | PHARMACEUTICAL COMPOSITIONS OF LIGNOCAINE HCL | SHILPA MEDICARE LIMITED (IN) | 2019-01-10 | — | — | WO | claimed |
| WO-2017001979-A1 | DIINDOLYL METHANE COMPOSITIONS, FORMULATIONS AND USE THEREOF | REFORM BIO INC. (CA) | 2017-01-05 | — | — | WO | claimed |
| EP-2934593-A2 | CABAZITAXEL COMPOSITION | Supratek Pharma, Inc. (CA) | 2015-10-28 | — | — | EP | claimed |
| EP-2854531-A1 | STABILIZED FORMULATIONS CONTAINING IODINATED CONTRAST AGENTS AND CYCLODEXTRINS | Verrow Pharmaceuticals, Inc. (US) | 2015-04-08 | — | — | EP | claimed |
| WO-2014122498-A2 | CABAZITAXEL COMPOSITION | SUPRATEK PHARMA INC. (CA) | 2014-08-14 | — | — | WO | claimed |
| WO-2014102731-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS OF ROMIDEPSIN | LEIUTIS PHARMACEUTICALS PVT. LTD (IN) | 2014-07-03 | — | — | WO | claimed |
| WO-2013180777-A1 | STABILIZED FORMULATIONS CONTAINING IODINATED CONTRAST AGENTS AND CYCLODEXTRINS | VERROW PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | WO | claimed |
| EP-2579869-A2 | FORMULATIONS INCLUDING AMIODARONE AND SALTS THEREOF AND METHODS OF THEIR MANUFACTURE AND USE | Baxter International Inc (US) | 2013-04-17 | — | — | EP | claimed |
| WO-2012078815-A1 | SUSTAINED RELEASE IMPLANTS CONTAINING A BIODEGRADABLE POLYMER, CYCLODEXTRIN AND POORLY WATER SOLUBLE ACTIVE COMPOUNDS | ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC (US) | 2012-06-14 | — | — | WO | claimed |
| WO-2011060253-A2 | METHODS OF TREATING DISEASES, PHARMACEUTICAL COMPOSITIONS, AND PHARMACEUTICAL DOSAGE FORMS | MYREXIS, INC. (US) | 2011-05-19 | — | — | WO | claimed |
| EP-4392030-A1 | TREATMENT OF COVID-19 | Oxygen Biotech LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024110851-A1 | INHIBITORS OF ROCK2 | GRAVITON BIOSCIENCE BV (NL) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024091826-A1 | LYOPHILIZED BENDAMUSTINE-CYCLODEXTRIN COMPOSITION | SOFTKEMO PHARMA INC. (CA) | 2024-05-02 | — | — | WO | disclosed |
| EP-4351565-A1 | USE OF MMP INHIBITORS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME | Foresee Pharmaceuticals Co., Ltd. (TW) | 2024-04-17 | — | — | EP | disclosed |
| WO-2006107902-A2 | USE OF SPIROSTENOLS TO TREAT MITOCHONDRIAL DISORDERS | SAMARITAN PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006044665-A2 | NEUROPROTECTIVE SPIROSTENOL PHARMACEUTICAL COMPOSITIONS | GEORGETOWN UNIVERSITY (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20050080006-A1 | Apo2 ligand/trail formulations | GENENTECH, INC. | 2005-04-14 | — | — | US | disclosed |
| WO-2005014010-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GEMCITABINE AND CYCLODEXTRINES | ELI LILLY AND COMPANY (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050020498-A1 | Apo-2 ligand/trail formulations | GENENTECH, INC. | 2005-01-27 | — | — | US | disclosed |